Free Newsletter
Animal data supports J&J;'s Alzheimer's vaccine
J&J's Alzheimer's research group at Janssen has found positive signs for bapineuzumab, its late-stage Alzheimer's therapeutic vaccine. In a study using mice, researchers found that those who were inoculated performed a simple task more effectively, which could mean the vax was successful at stopping amyloid plaque from binding with neurons. Story
More stories about Alzheimer's
Comments
Post new comment
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
More Research Reports >>
SHARE
WITH: